Stock Track | Eli Lilly Soars 5.11% in Pre-market on CVS GLP-1 Partnership and Novo Nordisk Pipeline Setbacks

Stock Track

Aug 05

Eli Lilly shares surged 5.11% in pre-market trading on Wednesday, driven by a newly announced collaboration with CVS Health and a boost from rival Novo Nordisk's disappointing pipeline updates.

The rally was sparked by CVS Health's announcement of a partnership with Eli Lilly to help eligible patients more easily access transparent pricing for Zepbound and Foundayo, two of Lilly's GLP-1 treatments. Under the collaboration, patients will be able to view pricing options through the CVS Health app and access same-day pickup at CVS pharmacies, along with expanded pharmacy support and $29 MinuteClinic online visits for eligible patients.

Adding to the positive sentiment, competitor Novo Nordisk faced investor disappointment after its earnings report, despite raising its full-year outlook. Investors focused on slightly weaker-than-expected sales for its new Wegovy pill and another trial setback for its next-generation obesity drug CagriSema. The setbacks have intensified scrutiny on Novo's pipeline and highlighted Eli Lilly's strengthening competitive position in the obesity drug market, which analysts project will exceed $100 billion annually by 2030.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1108686351"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1108686351\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1108686351?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-05 18:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108686351","market":"us","top_or_hot":-1,"title":"Stock Track | Eli Lilly Soars 5.11% in Pre-market on CVS GLP-1 Partnership and Novo Nordisk Pipeline Setbacks","media":"Stock Track","content":"<p>Eli Lilly shares surged 5.11% in pre-market trading on Wednesday, driven by a newly announced collaboration with CVS Health and a boost from rival Novo Nordisk's disappointing pipeline updates.</p><p>The rally was sparked by CVS Health's announcement of a partnership with Eli Lilly to help eligible patients more easily access transparent pricing for Zepbound and Foundayo, two of Lilly's GLP-1 treatments. Under the collaboration, patients will be able to view pricing options through the CVS Health app and access same-day pickup at CVS pharmacies, along with expanded pharmacy support and $29 MinuteClinic online visits for eligible patients.</p><p>Adding to the positive sentiment, competitor Novo Nordisk faced investor disappointment after its earnings report, despite raising its full-year outlook. Investors focused on slightly weaker-than-expected sales for its new Wegovy pill and another trial setback for its next-generation obesity drug CagriSema. The setbacks have intensified scrutiny on Novo's pipeline and highlighted Eli Lilly's strengthening competitive position in the obesity drug market, which analysts project will exceed $100 billion annually by 2030.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Eli Lilly Soars 5.11% in Pre-market on CVS GLP-1 Partnership and Novo Nordisk Pipeline Setbacks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Eli Lilly Soars 5.11% in Pre-market on CVS GLP-1 Partnership and Novo Nordisk Pipeline Setbacks\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-08-05 18:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Eli Lilly shares surged 5.11% in pre-market trading on Wednesday, driven by a newly announced collaboration with CVS Health and a boost from rival Novo Nordisk's disappointing pipeline updates.</p><p>The rally was sparked by CVS Health's announcement of a partnership with Eli Lilly to help eligible patients more easily access transparent pricing for Zepbound and Foundayo, two of Lilly's GLP-1 treatments. Under the collaboration, patients will be able to view pricing options through the CVS Health app and access same-day pickup at CVS pharmacies, along with expanded pharmacy support and $29 MinuteClinic online visits for eligible patients.</p><p>Adding to the positive sentiment, competitor Novo Nordisk faced investor disappointment after its earnings report, despite raising its full-year outlook. Investors focused on slightly weaker-than-expected sales for its new Wegovy pill and another trial setback for its next-generation obesity drug CagriSema. The setbacks have intensified scrutiny on Novo's pipeline and highlighted Eli Lilly's strengthening competitive position in the obesity drug market, which analysts project will exceed $100 billion annually by 2030.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LLY","symbol_name":"礼来","start_time":0,"source_url":"","article_id":"1108686351","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108686351","pubTimestamp":1785926828,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Eli Lilly shares surged 5.11% in pre-market trading on Wednesday, driven by a newly announced collaboration with CVS Health and a boost from rival Novo Nordisk's disappointing pipeline updates.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LLY":"礼来"},"translate_title":"股票跟踪 | 由于 CVS GLP-1 合作伙伴关系和诺和诺德管道受挫，礼来公司盘前股价飙升 5.11%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1},"content_text":"Eli Lilly shares surged 5.11% in pre-market trading on Wednesday, driven by a newly announced collaboration with CVS Health and a boost from rival Novo Nordisk's disappointing pipeline updates.The rally was sparked by CVS Health's announcement of a partnership with Eli Lilly to help eligible patients more easily access transparent pricing for Zepbound and Foundayo, two of Lilly's GLP-1 treatments. Under the collaboration, patients will be able to view pricing options through the CVS Health app and access same-day pickup at CVS pharmacies, along with expanded pharmacy support and $29 MinuteClinic online visits for eligible patients.Adding to the positive sentiment, competitor Novo Nordisk faced investor disappointment after its earnings report, despite raising its full-year outlook. Investors focused on slightly weaker-than-expected sales for its new Wegovy pill and another trial setback for its next-generation obesity drug CagriSema. The setbacks have intensified scrutiny on Novo's pipeline and highlighted Eli Lilly's strengthening competitive position in the obesity drug market, which analysts project will exceed $100 billion annually by 2030.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}